Approximately 50% of primary and metastatic UM tumors express PRAME [121,122], and T cells engineered with PRAME-specific TCRs have demonstrated selective cytotoxicity against PRAME-positive melanoma cell lines [123]. Here, PRAME is linked to melanoma.